Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01199094|
Recruitment Status : Completed
First Posted : September 10, 2010
Last Update Posted : September 10, 2010
|Condition or disease|
Cases and controls are closely matched on age and sex and evaluated cross-sectionally.
Dual x-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HR-pQCT) are used in order to evaluate bone density as well as microarchitecture. Bone turnover markers and body composition are also measured.
|Study Type :||Observational|
|Actual Enrollment :||38 participants|
|Observational Model:||Case Control|
|Official Title:||Clinical Assessment of Patients With High Bone Mass Due to Mutation in Low Density Lipoprotein l Receptor 5|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||April 2010|
|Actual Study Completion Date :||June 2010|
Patients with mutation in the Lrp5 gene
Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
- Bone microarchitecture as assessed by high resolution quantitative computed tomography (HR-pQCT) [ Time Frame: 12 weeks ]HR-pQCT is used to evaluate bone microarchitecture, i.e. bone trabeculae, cortical thickness and trabecular number. Aim is to test if the microarchitecture of these patients are different that observed in normal controls
- Changes in bone turnover markers [ Time Frame: 12 weeks ]Markers of bone resorption and formation are investigated.
- Bone mineral density [ Time Frame: 12 weeks ]DXA is used to evaluate bone mineral density at total hip, spine, whole body and forearm.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01199094
|Odense University Hospital, Osteoporosis Clinic|
|Odense, Denmark, 5000|
|Principal Investigator:||Kim Brixen, Professor||Odense University Hospital|